Abstract: A process for the preparation of a pure form of protein, wherein the protein is protease activating blood clotting factor VII, the proenzyme for the protease, or a mixture of both the-protease and the proenzyme, is described. The protein is obtained from biological fluids or through genetic engineering and is isolated by anion- and/or cation-exchange chromatography at a pH below the isoelectric point of the protein to be isolated, or by a combination of anion- or cation-exchange chromatography with a chromatography process and/or fractional precipitation at pH between 2.5 and 9.0.

Abstract: A process for the preparation in pure form of the protease activating blood clotting factor VII and/or its proenzyme by the use of a chromatography separation processes and/or fractional precipitation is described. The process used may include adsorption on calcium phosphate/hydroxyapatite, a hydrophobic matrix, a chelate matrix, a matrix on which heparin or a substance related to heparin, such as heparin sulfate or dextran sulfate, is immobilized, or a matrix that is coated with an immobilized monoclonal or polyclonal antibody directed against the protein to be isolated, or F(ab) or F(ab)2 fragments of antibodies directed against the protein to be isolated. A pharmaceutical preparation and a reagent are described which contain the said protease and/or its proenzyme.

Abstract: A monoclonal antibody which inhibits the blood clotting factor VII-activating protease and its proenzyme and a blood clotting factor VII-activating protease, stabilized by the addition of said monoclonal antibody, and its proenzyme are described. A suitable monoclonal antibody is produced by hybridoma cell line DSM ACC 2533. The application of the inhibitory, monoclonal antibody in the stabilization of blood clotting preparations and in preparations for reducing the coagulability of the blood is disclosed.

Abstract: A protease for activating the blood clotting factor VII is described, which

Abstract: A procedure for the determination of the activity of the protease which activates blood clotting factor VII from protein solutions is describes, in which

Abstract: The invention relates to a process for purifying factor VII and/or activated factor VIIa (F VII/F VIIa) by means of binding to immobilized soluble thromboplastin.

Abstract: A protease for activating the blood clotting factor VII, which is inhibited by the presence of aprotinin, is increased in its activity by calcium ions and/or heparin or heparin-related substances, and in SDS-PAGE, on subsequent staining in the non-reduced state, comprises one or more bands in the molecular weight range from 50 to 75 kDa; and in SDS-PAGE, on subsequent staining in the reduced state, comprises a band at 40 to 55 kDa, one or more bands in the molecular weight range from 10 to 35 kDa, and a band in the molecular weight range between 60 and 65 kDa, which corresponds to a proenzyme. Pharmaceutical preparations containing the protease or its proenzyme are suitable for the prophylaxis and treatment of bleeding events, e.g. in the presence of FVIII inhibitors, wound healing and for the treatment of disorders which are caused by fibrin-containing thrombin.

Abstract: Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutant comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 1601, is described. The corresponding protease has a Glu/Gin exchange at amino acid position 393 and/or a Gly/Glu exchange at amino acid position 534. Furthermore, diagnostic methods which are used for detecting FSAP in body fluids or tissue cells and also for identifying patients with genetic heterozygous or homozygous FSAP expression are described. In addition, antibodies against FSAP and its mutants are disclosed and diagnostic methods which can be used to detect antibodies against FSAP and its mutants are specified.

Abstract: A stabilized liquid preparation of the protease which activates blood coagulation factor VII, or of its proenzyme, which comprises;

Abstract: A stabilized protein preparation is described which contains no antithrombin III and is protected against loss of activity during pasteurization by the addition of stabilizers which comprise one or more saccharides as a mixture with more than 0.5 mol/l of one or more amino acids chosen from the group arginine, lysine, histidine, phenylalanine, tryptophan, tyrosine, aspartic acid and its salts or glutamic acid and its salts. Glycine and/or glutamine can also be additionally added to each of these amino acids. A process for the viral inactivation or viral depletion of a protein preparation of this type which contains the abovementioned stabilizers and is subjected to pasteurization or viral depletion by filtration, centrifugation or treatment with detergents or bactericidal or virucidal agents is also described.

Abstract: The invention relates to a process for purifying factor VII and/or activated factor VIIa (F VII/F VIIa) by means of binding to immobilized soluble thromboplastin.

Abstract: The invention relates to a method for the quantification of coagulation factor VIIa (F VIIa) in FVIIa- or FVII/FVIIa-containing solutions by means of selective binding to immobilized soluble thromboplastin.

Abstract: A printed circuit board and a method for making same is disclosed whereby a very high wiring density is provided in those regions of the printed circuit board in which external components (e.g., semiconductor chips) are to be attached directly. An automated registration routine permits very precise registration and positioning in those regions.

Abstract: A steering column for a vehicle having an outer housing fixedly mounted to the vehicle with a corrugated tubular section which is compressible upon application of axial force. A reinforcing sleeve is mounted to the outer housing with a sliding fit. The collapsible outer housing is supported by the reinforcing sleeve.

Abstract: The steering wheel column and/or the bearing for the steering wheel column in a motor vehicle is pushed or pulled away from a position in front of the driver in the event of a head-on collision whose intensity exceeds a preselected minimum value. The displacing unit which is activated in the event of head-on collision of preselected minimum intensity (e.g., a collision which causes the engine block and/or the transmission case to move rearwardly with reference to the frame of the motor vehicle) can entrain the steering wheel column and/or the bearing for the steering wheel column by way of a carrier which is pivotably mounted adjacent the steering wheel column or its bearing and has one or more projections with cutting edges penetrating into the steering wheel column and/or bearing in response to activation of the displacing unit.

Abstract: A telescopable, height-adjustable steering column for power vehicles comprises an inner pipe provided with a sliding surface, an outer pipe provided with a sliding surface cooperating with the sliding surface of the inner pipe. One of the pipes is displaceable relative to the other of the pipes. An element for closing the tolerance gap between the sliding surfaces of the inner and outer pipes and includes two wedge members located between the pipes and displaceable under a spring action transversely to an axis of the steering column over two inclined planes.

Abstract: In the preparation of parenteral solutions for the therapy and prophylaxis of thromboses and embolisms, because of the poor solubility of t-PA hitherto either the infusion of very large volumes has been necessary, or else a solution with a low volume and a high t-PA concentration has been prepared at the expense of setting up a non-physiologically low pH of 2 to 5.Hence, the present invention relates to a process for the preparation of a solution of high concentration of a protein having plasminogen activator activity, where an increase in stability and solubility is achieved by adding at least two substances from the group of D- and/or L-amino acids, their salts, derivatives or homologs. This invention also relates to a process for the pasteurization of a protein solution having t-PA activity, and to a t-PA-containing solution prepared by the claimed process, and to the use of this solution as a fibrinolytic in human and veterinary medicine.

Abstract: A manually height-adjustable steering column of power vehicle comprises an inner tube and an outer tube together forming a telescopeable tubular element, the inner and outer tubes having an overlapping and displacement region, the outer tube having a multi-cornered cross-section, two sliding bushes arranged in the region at a distance from one another and having sliding surfaces associated with the outer tube in the region, a rotary bar extending inside the inner tube and having two end pieces one of which is connected with the inner tube, one of the sliding bushes being arranged in the vicinity of an end of the inner tube and being mounted on the other of the end pieces, the other of the sliding bushes being mounted on an outer surface of the inner tube, the sliding surfaces of the one bush being offset relative to the sliding surfaces of the other sliding bush and orientable relative to sliding surfaces of the outer tube by a rotary deformation of the rotary bar.

Abstract: A solid fibrinogen formulation is described, which formulation contains, in addition to fibrinogen, a substance containing the urea or guanidine radical, and a process for its preparation. This formulation is used for the preparation of a fibrinogen solution which is suitable as an adhesive for human and animal tissue and as a fibrinogen concentrate for intravenous administration.